Jakub Wojtowicz

Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s Disease

Randall J. Bateman, Janice Smith, Michael Donohue et al. · New England Journal of Medicine · 2023 · 239 citations · Full text

Amyloid‐Related Imaging Abnormalities in the <scp>DIAN‐TU</scp>‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease

Nelly Joseph‐Mathurin, Jorge J. Llibre‐Guerra, Yan Li et al. · Annals of Neurology · 2022 · 34 citations · Full text

Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease

Stephen Salloway, Jakub Wojtowicz, Nicola Voyle et al. · JAMA Neurology · 2024 · 28 citations · Full text

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial

Randall J. Bateman, Yan Li, Eric McDade et al. · The Lancet Neurology · 2025 · 26 citations

Neurodegenerative Diseases, Geriatric Neurology, Alzheimer's Disease +12

Comparing ARIA‐E severity scales and effects of treatment management thresholds

Gregory Klein, Marzia A. Scelsi, Jerome Barakos et al. · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 2022 · 12 citations · Full text